StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

Gain Therapeutics cash

Cash and short-term investments held at the end of each period.

Gain Therapeutics's cash was $13.08M at Jun 30, 2026. For fiscal 2025 it was $20.84M, up 100.0% from the year before. The highest annual figure on record is $36.91M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$20.84M+100.0%
FY2024Dec 31, 2024$10.42M-38.0%
FY2023Dec 31, 2023$16.80M-16.7%
FY2022Dec 31, 2022$20.17M-45.4%
FY2021Dec 31, 2021$36.91M+391.9%
FY2020Dec 31, 2020$7.50M+2292.2%
FY2019Dec 31, 2019$313.70K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$13.08M+94.4%
Q1 FY2026Mar 31, 2026$16.54M+81.7%
Q4 FY2025Dec 31, 2025$20.84M+100.0%
Q3 FY2025Sep 30, 2025$8.81M-27.1%
Q2 FY2025Jun 30, 2025$6.73M-60.3%
Q1 FY2025Mar 31, 2025$9.10M-28.3%
Q4 FY2024Dec 31, 2024$10.42M-38.0%
Q3 FY2024Sep 30, 2024$12.08M-1.8%
Q2 FY2024Jun 30, 2024$16.97M+4.6%
Q1 FY2024Mar 31, 2024$12.70M-28.8%
Q4 FY2023Dec 31, 2023$16.80M-16.7%
Q3 FY2023Sep 30, 2023$12.30M-46.0%
Q2 FY2023Jun 30, 2023$16.22M-33.2%
Q1 FY2023Mar 31, 2023$17.85M-48.1%
Q4 FY2022Dec 31, 2022$20.17M-45.4%
Q3 FY2022Sep 30, 2022$22.76M-44.5%
Q2 FY2022Jun 30, 2022$24.28M-43.8%
Q1 FY2022Mar 31, 2022$34.37M-26.3%
Q4 FY2021Dec 31, 2021$36.91M+391.9%
Q3 FY2021Sep 30, 2021$41.01M+342.0%
Q2 FY2021Jun 30, 2021$43.20M+8312.1%
Q1 FY2021Mar 31, 2021$46.64M+4834.5%
Q4 FY2020Dec 31, 2020$7.50M+2292.2%
Q3 FY2020Sep 30, 2020$9.28M–
Q2 FY2020Jun 30, 2020$513.60K–
Q1 FY2020Mar 31, 2020$945.11K–
Q4 FY2019Dec 31, 2019$313.70K–

More Gain Therapeutics figures

See a number that looks wrong?